SONAR
—
RCTs
Clinical literature
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.
Evidence intelligence
Your marketing intelligence gets smarter everyday.
Over time, the evidence map around your drug gets denser, the connections sharper, the picture clearer. It doesn't just keep up — it gets smarter.
- 200+ million academic papers
- 500,000+ clinical trials
- Current news and reports
- ComplyRx engine
Initialising sweep…0 / 28 nodes
Now in private beta
Followtheevidence.Leadthemarket.
Typeadrug.Watchfiveintelligencelayersresolveatonce.
- Automated evidence sweep
- Clinical trial intelligence
- Competitor positioning
- MLR-ready claim drafts
- Cited answers on demand
- Real-time drug news
PIPELINE
—
phase 2–4
Active trials
LABELS
—
label events
Regulatory events
SIGNAL
—
priority alerts
Market signal
RECON
—
overlap drugs
Competitive overlap
Night Agent
While you sleep,
the Night Agent works.
Every night at midnight, Night Agent re-sweeps your tracked drugs, detects what's changed since the last run, and surfaces only material signals — so you wake up to actionable evidence, not noise.
Tonight · 6 events
23:47 BSTAspirin·EVIDENCE·6h ago
New meta-analysis indexed
Consensus added a 2024 meta-analysis (n = 12,184) on aspirin in primary CV prevention. Confidence: high. Reinforces ASPREE.
View in Signal →Aspirin·CATALYST·18h ago
USPSTF advisory committee scheduled
Advisory hearing on May 14 — potential changes to primary-prevention recommendation. Out-of-band synthesis triggered at 00:04.
View in Sonar →Plavix·DELTA·22h ago
EU label revision detected
Plavix (clopidogrel) EU prescribing information updated — bleeding-risk monitoring section revised. Affects Recon competitor profile.
View in Recon →Aspirin·COMPLETE·7h ago
Nightly run complete
No new signals beyond entries above. Evidence base updated, no claim revisions needed.
No action required